氯法齐明在耐多药肺结核治疗中的临床价值  

Clinical value of clofazimine in the treatment of multi-drug resistant pulmonary tuberculosis

作　　者：吴素方[1] 郑淑兰[1] 刘新[1] 梁丽丽[1] WU Su-fang;ZHENG Shu-lan;LIU Xing;LIANG Li-li(He′nan Thoracic Hospital,Henan Zhengzhou 450003,China)

机构地区：[1]河南省胸科医院,河南郑州450003

出　　处：《江苏预防医学》2020年第1期26-28,共3页Jiangsu Journal of Preventive Medicine

基　　金：2015年度河南省重点科技攻关项目:缩短敏感肺结核治疗疗程的研究(152102310152)。

摘　　要：目的探讨氯法齐明在耐多药肺结核治疗中的临床价值。方法选取2015-2017年在河南省胸科医院治疗的耐多药肺结核患者110例,随机分为对照组(n=57)和观察组(n=53),分别给予常规治疗及在此基础上加用氯法齐明治疗,观察两组痰菌阴转、空洞缩小、病灶吸收及不良反应,同时检测治疗前后血管活性肠肽(VIP)和干扰素-"(IFN-")。结果观察组痰菌转阴率、空洞缩小率和治疗成功率分别为92.45%、92.00%和83.02%,均高于对照组,差异均有统计学意义(χ^2值分别为7.776、9.669和6.340,P值均<0.05);病灶吸收有效率达到100.00%,优于对照组,差异有统计学意义(Z=-3.894,P<0.05);观察组治疗后VIP明显低于对照组,IFN-"明显高于对照组,以上差异均有统计学意义(t值分别为-11.428、8.955,P值均<0.05);两组不良反应发生率差异无统计学意义(χ^2=3.062,P>0.05)。结论氯法齐明在耐多药肺结核治疗中有较好的应用价值,能提高治疗效果,且不明显增加不良反应发生。Objective To explore the clinical value of clofazimine in the treatment of multi-drug resistant pulmonary tuberculosis(MDR-TB).Methods A total of 110 MDR-TB patients treated in He′nan Thoracic Hospital from 2015 to 2017 were selected and randomly divided into observation group(n=53)and control group(n=57).The control group was given routine treatment,while the observation group was given additional clofazimine treatment.The sputum negative transformation rate,cavity shrinkage rate,lesion absorption rate and complications were observed in both groups,the vasoactive intestinal peptide(VIP)and interferon-"(IFN-")levels were detected before and after treatment.Results The sputum negative rate,cavity shrinkage rate and treatment success rate of the observation group were 92.45%,92.00% and 83.02%,respectively,which were significantly higher than those of the control group(#2 values were 7.776,9.669 and 6.340,all P<0.05).The effective lesion absorption rate in the observation group was 100.00%,which was better than that in the control group(Z=-3.894,P<0.05).After treatment,the VIP of the observation group was significantly lower than that of the control group,while the IFN-" level was significantly higher than that of the control group(t=-11.428,8.955,all P<0.05);there was no significant difference for the incidence of complications between the observation group and the control group(#2=3.062,P>0.05).Conclusions Clofazimine has good clinical application value in the treatment of MDR-TB patients,which can improve the treatment effect without significantly increasment complications incidence.

关 键 词：氯法齐明 耐多药肺结核 临床价值 

分 类 号：R521[医药卫生—内科学]